Does Dupilumab Affect Vaccine Response?

Patients with moderate-to-severe atopic dermatitis have shown improvement when treated with dupilumab, a monoclonal antibody that targets the IL-4 receptor a subunit, which inhibits signaling of both IL-4 and IL-13. There are many immune factors that contribute to immune response, but a recent study sought to determine whether dupilumab might affect patients’ responses to commonly …